Common Chemotherapy Side Effects and How Nurses Manage Them | Megha Shah, DNP, FNP, OCN
Chemotherapy works by targeting rapidly dividing cells. That mechanism is what makes it effective against cancer, and it is also why it causes side effects. Healthy cells that divide quickly — the lining of the gastrointestinal tract, hair follicles, and bone marrow — are caught in the crossfire. As an oncology nurse practitioner, much of my clinical work involves recognizing, assessing, and managing the side effects patients experience during treatment.
This article covers the five side effects I see most often in the outpatient infusion setting: nausea and vomiting, fatigue, peripheral neuropathy, mucositis, and myelosuppression. For each one, I have included the key nursing assessment priorities and the patient teaching points that actually make a difference.
Nausea and Vomiting
Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared side effects among patients starting treatment, and managing it well requires anticipating it before it starts.
Clinical background. CINV is classified based on timing. Acute CINV occurs within 24 hours of chemotherapy administration. Delayed CINV develops 24 hours to several days after treatment and is particularly common with platinum-based agents such as cisplatin. Anticipatory CINV is a conditioned response that develops in patients who have previously experienced nausea — it can occur before the infusion even starts, triggered by sights, smells, or the drive to the clinic.
The emetogenicity of the chemotherapy regimen drives antiemetic selection. Highly emetogenic regimens, including cisplatin-based and anthracycline-cyclophosphamide combinations, require aggressive prophylaxis with a five-hydroxytryptamine type 3 receptor antagonist, a neurokinin-1 receptor antagonist, dexamethasone, and in some cases olanzapine.
Nursing assessment. At every visit, assess the frequency, severity, and timing of nausea or vomiting since the last treatment. Ask patients specifically whether the nausea is limiting their oral intake. A patient who cannot maintain adequate hydration or nutrition is at risk for dehydration, electrolyte imbalances, and dose delays. Use a validated tool — the Rhodes Index or a simple 0-to-10 patient-reported scale — to track severity over time.
Patient teaching. Teach patients to take their prescribed antiemetics on a schedule rather than waiting until nausea begins. Once nausea is established, it is harder to control. Encourage small, frequent meals, bland foods, and adequate fluid intake. Ginger — in ginger chews, ginger ale made with real ginger, or ginger tea — has modest evidence for reducing CINV severity and is safe for most patients. Advise patients to avoid strong odors, which can trigger anticipatory nausea, and to keep rescue antiemetics on hand and accessible at home.
Fatigue
Cancer-related fatigue is the most commonly reported symptom across all cancer diagnoses and treatment types, and it is frequently undertreated. Unlike ordinary tiredness, cancer-related fatigue is not consistently relieved by rest and can persist long after treatment ends.
Clinical background. The mechanisms are multifactorial. Inflammation, anemia, sleep disturbance, poor nutritional status, deconditioning, and the direct effects of cytotoxic agents all contribute. Fatigue is also worsened by undertreated pain, depression, and anxiety — comorbidities that are common in the oncology population and deserve their own screening.
Nursing assessment. Fatigue should be screened at every visit using a validated tool. The Brief Fatigue Inventory and the FACT-F subscale are both used in clinical and research settings. When fatigue is rated moderate to severe, a more thorough assessment is warranted: rule out anemia and thyroid dysfunction, assess sleep quality, screen for depression, and review current medications for agents that cause drowsiness or sedation.
Patient teaching. Evidence supports structured, moderate-intensity physical activity as the most effective intervention for cancer-related fatigue. This may feel counterintuitive to patients who feel exhausted, but even a short daily walk has been shown in clinical trials to reduce fatigue severity. Energy conservation strategies — prioritizing activities, delegating tasks, scheduling high-priority activities for times of peak energy — help patients use what energy they have more intentionally. Teach patients to report fatigue that is significantly interfering with daily function rather than accepting it as a given.
Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is nerve damage caused by certain chemotherapy agents, most commonly taxanes (paclitaxel, docetaxel), platinum compounds (oxaliplatin, cisplatin), and vinca alkaloids (vincristine, vinblastine). It is one of the most dose-limiting toxicities in oncology and can persist or become permanent in some patients.
Clinical background. CIPN typically presents as numbness, tingling, burning, or shooting pain in the hands and feet in a stocking-and-glove distribution. Patients receiving oxaliplatin — commonly used in colorectal cancer regimens — often experience a distinctive acute cold-related dysesthesia that begins during or just after infusion. This is different from the cumulative sensory neuropathy that develops over time with ongoing oxaliplatin exposure.
Nursing assessment. Assess for neuropathy symptoms at every visit in patients receiving neurotoxic agents. The CIPN Assessment Tool and patient-reported outcome tools like the NCI PRO-CTCAE provide structured ways to track severity. Pay particular attention to functional impairment: a patient who is dropping objects, tripping, or struggling to button clothing has functional neuropathy that significantly affects safety and quality of life. Motor involvement, though less common, requires prompt reporting to the provider.
Patient teaching. Teach patients to report new or worsening symptoms promptly — dose modification or treatment hold decisions are often guided by patient-reported symptoms, and patients need to understand that reporting early helps protect them. Advise patients to inspect their feet daily for cuts or wounds they may not be able to feel. Fall precautions are important for patients with lower extremity neuropathy: remove loose rugs, use handrails, and wear supportive footwear. There is no strongly evidence-supported pharmacologic agent for CIPN prevention, but duloxetine has shown modest benefit for treatment of established CIPN pain in clinical trials.
Mucositis
Oral mucositis is inflammation and ulceration of the mucous membranes of the mouth and gastrointestinal tract. It is common with regimens that include methotrexate, fluorouracil, and anthracyclines, and it is nearly universal in patients undergoing high-dose chemotherapy prior to stem cell transplant.
Clinical background. Mucositis develops because chemotherapy damages the rapidly dividing cells of the oral epithelium. The breakdown of the mucosal barrier causes pain, difficulty eating and drinking, and increased infection risk. Severe mucositis can require opioid analgesia, parenteral nutrition, and hospitalization.
Nursing assessment. Assess the oral cavity at each visit during high-risk regimens. Use the WHO or NCI CTCAE grading scale consistently. Ask patients about pain with eating, drinking, or swallowing. Grade 3 mucositis — painful erythema, edema, and ulcers, requiring a liquid diet — and Grade 4 — requiring parenteral nutrition — both warrant escalation to the provider team. Also assess the patient’s oral hygiene routine and dental history, as poor baseline oral health increases mucositis risk.
Patient teaching. Encourage patients to begin a preventive oral care routine before starting chemotherapy if time allows. This includes brushing with a soft-bristled toothbrush after each meal, rinsing with a bland salt and baking soda rinse four to six times daily, staying hydrated, and avoiding alcohol-based mouthwashes, which are drying. Patients receiving fluorouracil infusions may benefit from oral cryotherapy — sucking on ice chips during infusion — which has demonstrated efficacy in reducing mucositis severity by causing vasoconstriction in the oral mucosa. Advise patients to eat soft, moist foods and to avoid acidic, spicy, or rough-textured foods when mouth soreness develops.
Myelosuppression
Myelosuppression — suppression of bone marrow function leading to decreased production of blood cells — is one of the most clinically significant side effects of cytotoxic chemotherapy. It manifests as neutropenia (low neutrophils), thrombocytopenia (low platelets), and anemia (low red blood cells), each with distinct risks and management priorities.
Clinical background. The nadir, or the point of lowest blood counts, typically occurs seven to fourteen days after chemotherapy administration, though the timing varies by regimen. Neutropenia is the most immediately dangerous manifestation because it impairs the immune response to infection. A patient with an absolute neutrophil count below 500 cells/mcL is at high risk for serious bacterial infection. Fever in a neutropenic patient is an oncologic emergency.
Nursing assessment. Review labs before every treatment. If absolute neutrophil count is below threshold for the prescribed regimen, hold the infusion and notify the provider. Assess for signs and symptoms of infection at each visit, including fever, chills, cough, dysuria, and skin changes. For patients with thrombocytopenia, assess for unusual bruising, bleeding gums, nosebleeds, and petechiae. For patients with anemia, assess for dyspnea on exertion, fatigue, pallor, and heart rate changes.
Patient teaching. Patients receiving regimens with high myelosuppression risk need to understand the signs of neutropenic fever and when to seek emergency care immediately. A temperature of 100.4°F (38°C) or higher in a neutropenic patient requires a call to the care team and, in most cases, immediate evaluation. Teach patients to avoid sick contacts, wash hands frequently, and report any fever promptly — do not wait to see if it resolves. For patients on growth factor support such as filgrastim, teach the purpose of the medication, the injection technique, and the common bone pain side effect.
Managing chemotherapy side effects is not a peripheral part of oncology nursing — it is the core of it. When nurses assess consistently, document carefully, and teach patients how to recognize and report problems early, they reduce hospitalizations, protect treatment continuity, and make an enormous difference in the day-to-day experience of people going through cancer treatment. The clinical knowledge matters. So does the relationship with the patient who trusts you to tell them the truth about what to expect.